Bengaluru-based startup Mestastop Solutions has partnered with Switzerland-based Ectica Technologies to pursue novel platform creation on cancer metastasis that would build upon Ectica and Mestastop’s proprietary technologies.

Mestastop has successfully created three platform technologies around cancer metastasis drug discovery and early predictive diagnostics. Ectica Technologies is a spin-off company of ETH Zurich and University Hospital Zurich and develops advanced hydrogel-based co-cultures platforms for in vitro tumour-stroma interaction studies compatible with high-content screening.

All pre-existing intellectual property will remain the property of the respective party, and either party shall have no right or license to the other’s intellectual property. The objective of this collaboration will be to explore the possibilities of using both technologies to build a novel system that will support researchers in cancer metastasis research. 

Speaking on this partnership, Dr Arnab Roy Chowdhury, Founder and Director of Mestastop Solutions, said, “We now want to explore the organotropism around metastasis, and the novel Ectica co-culture platforms are the best way to study that."